|
Solitary fibrous tumor
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, we described a cohort of 41 patients with solitary fibrous tumor of the extremities and evaluated the prognostic role of clinical and histological features, presence of C228T and C250T mutations at the TERT promoter region, and NAB2-STAT6 fusion variants.
|
31463729 |
2020 |
|
Solitary fibrous tumor
|
0.600 |
Biomarker
|
disease |
BEFREE |
Asymptomatic normal-coloured submucosal nodules located in the buccal mucosa and tongue in adult patients are suggestive of oral solitary fibrous tumour, but only a careful microscopic examination can differentiate benign from malignant variants and the use of immunohistochemistry (CD34, Bcl-2, CD99 and STAT6), and cytogenetic studies (NAB2-STAT6) contribute significantly to confirm the diagnosis of solitary fibrous tumour in difficult cases.
|
31424136 |
2020 |
|
Solitary fibrous tumor
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Solitary fibrous tumors (SFTs) are NAB2-STAT6 fusion-associated neoplasms.
|
31321477 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Solitary fibrous tumors (SFTs) are NAB2-STAT6 fusion-associated neoplasms.
|
31321477 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Co-injection of NAB2-overexpressing CAFs with FaDu spheroids into mice enhanced the growth of tumors.
|
30893927 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
NAB 2-Expressing Cancer-Associated Fibroblast Promotes HNSCC Progression.
|
30893927 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
NAB 2-Expressing Cancer-Associated Fibroblast Promotes HNSCC Progression.
|
30893927 |
2019 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
These data suggest that NAB2-overexpressing CAFs promotes HNSCC progression and is a potential therapeutic target for preventing HNSCC metastasis.
|
30893927 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.020 |
Biomarker
|
disease |
BEFREE |
NAB2 was detected in interstitial CAFs in primary and metastatic lymph node tissues of HNSCC patients.
|
30893927 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The molecular mechanism through which NAB2 is involved in cancer is largely unknown.
|
30845713 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
The molecular mechanism through which NAB2 is involved in cancer is largely unknown.
|
30845713 |
2019 |
|
Neoplasm Metastasis
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
TCGA data analysis of 483 HNSCC tumors showed that higher levels of both <i>EGR1</i> and <i>NAB2</i> mRNA were significantly associated with metastasis, corresponding to in vitro results.
|
30845713 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The correlation between <i>EGR1</i>-<i>NAB2</i> expression and metastatic status was investigated using The Cancer Genome Atlas (TCGA) for HNSCC patients.
|
30845713 |
2019 |
|
Solitary fibrous tumor
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This review addresses three main neoplastic categories that are associated with specific paraneoplastic phenomena: (1) neoplasms having in common the presence of diffuse mixed inflammatory infiltration (closely simulating an inflammatory pseudotumor) and frequently associated with constitutional symptoms; (2) neoplasms with undifferentiated, anaplastic or rhabdoid cell morphology (frequently SWI/SNF-deficient) associated with diverse paraneoplastic manifestations; and (3) paraneoplasia associated with neoplasms carrying specific gene fusions such as solitary fibrous tumor (STAT6-NAB2 gene fusions), infantile fibrosarcoma and congenital mesoblastic nephroma (ETV6-NTRK3 gene fusions), and angiomatoid fibrous histiocytoma (EWSR1-CREB1 & EWSR1-ATF1 fusions).
|
30819530 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review addresses three main neoplastic categories that are associated with specific paraneoplastic phenomena: (1) neoplasms having in common the presence of diffuse mixed inflammatory infiltration (closely simulating an inflammatory pseudotumor) and frequently associated with constitutional symptoms; (2) neoplasms with undifferentiated, anaplastic or rhabdoid cell morphology (frequently SWI/SNF-deficient) associated with diverse paraneoplastic manifestations; and (3) paraneoplasia associated with neoplasms carrying specific gene fusions such as solitary fibrous tumor (STAT6-NAB2 gene fusions), infantile fibrosarcoma and congenital mesoblastic nephroma (ETV6-NTRK3 gene fusions), and angiomatoid fibrous histiocytoma (EWSR1-CREB1 & EWSR1-ATF1 fusions).
|
30819530 |
2019 |
|
Inflammatory Myofibroblastic Tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
This review addresses three main neoplastic categories that are associated with specific paraneoplastic phenomena: (1) neoplasms having in common the presence of diffuse mixed inflammatory infiltration (closely simulating an inflammatory pseudotumor) and frequently associated with constitutional symptoms; (2) neoplasms with undifferentiated, anaplastic or rhabdoid cell morphology (frequently SWI/SNF-deficient) associated with diverse paraneoplastic manifestations; and (3) paraneoplasia associated with neoplasms carrying specific gene fusions such as solitary fibrous tumor (STAT6-NAB2 gene fusions), infantile fibrosarcoma and congenital mesoblastic nephroma (ETV6-NTRK3 gene fusions), and angiomatoid fibrous histiocytoma (EWSR1-CREB1 & EWSR1-ATF1 fusions).
|
30819530 |
2019 |
|
Histiocytoma, Angiomatoid Fibrous
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This review addresses three main neoplastic categories that are associated with specific paraneoplastic phenomena: (1) neoplasms having in common the presence of diffuse mixed inflammatory infiltration (closely simulating an inflammatory pseudotumor) and frequently associated with constitutional symptoms; (2) neoplasms with undifferentiated, anaplastic or rhabdoid cell morphology (frequently SWI/SNF-deficient) associated with diverse paraneoplastic manifestations; and (3) paraneoplasia associated with neoplasms carrying specific gene fusions such as solitary fibrous tumor (STAT6-NAB2 gene fusions), infantile fibrosarcoma and congenital mesoblastic nephroma (ETV6-NTRK3 gene fusions), and angiomatoid fibrous histiocytoma (EWSR1-CREB1 & EWSR1-ATF1 fusions).
|
30819530 |
2019 |
|
Congenital Mesoblastic Nephroma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This review addresses three main neoplastic categories that are associated with specific paraneoplastic phenomena: (1) neoplasms having in common the presence of diffuse mixed inflammatory infiltration (closely simulating an inflammatory pseudotumor) and frequently associated with constitutional symptoms; (2) neoplasms with undifferentiated, anaplastic or rhabdoid cell morphology (frequently SWI/SNF-deficient) associated with diverse paraneoplastic manifestations; and (3) paraneoplasia associated with neoplasms carrying specific gene fusions such as solitary fibrous tumor (STAT6-NAB2 gene fusions), infantile fibrosarcoma and congenital mesoblastic nephroma (ETV6-NTRK3 gene fusions), and angiomatoid fibrous histiocytoma (EWSR1-CREB1 & EWSR1-ATF1 fusions).
|
30819530 |
2019 |
|
Solitary fibrous tumor
|
0.600 |
Biomarker
|
disease |
BEFREE |
STAT6 stain has proved to be a good surrogate marker for the genetic alteration (NAB2-STAT6 gene fusion) in solitary fibrous tumor (SFT).
|
30664532 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NAB2-STAT6 fusion was detected in 99 of 111 successfully tested tumors (89%) including the single STAT6 immunonegative tumor.
|
30584643 |
2019 |
|
Hemangiopericytoma of meninges
|
0.020 |
Biomarker
|
disease |
BEFREE |
The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma.
|
30584643 |
2019 |
|
Intellectual Disability
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Importantly, mutations in the gene encoding the human Nab2 orthologue ZC3H14 and cause intellectual disability.
|
30578643 |
2019 |
|
hemangiopericytoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
The 2016 central nervous system (CNS) World Health Organisation (WHO) Update has merged the entities of meningeal solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) into a single entity based on the presence of the nerve growth factor 1A (NGFI-A) binding protein 2 (NAB2)- signal transducer and activator of transcription 6 (STAT6) gene fusion in these tumors.
|
30233017 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The 2016 central nervous system (CNS) World Health Organisation (WHO) Update has merged the entities of meningeal solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) into a single entity based on the presence of the nerve growth factor 1A (NGFI-A) binding protein 2 (NAB2)- signal transducer and activator of transcription 6 (STAT6) gene fusion in these tumors.
|
30233017 |
2019 |
|
Hereditary pancreatitis
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
The 2016 central nervous system (CNS) World Health Organisation (WHO) Update has merged the entities of meningeal solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) into a single entity based on the presence of the nerve growth factor 1A (NGFI-A) binding protein 2 (NAB2)- signal transducer and activator of transcription 6 (STAT6) gene fusion in these tumors.
|
30233017 |
2019 |